Yisak W, von Bahr C, Farde L, Grind M, Mattila M, Ogenstad S
Astra Research Centre, Södertälje, Sweden.
Acta Psychiatr Scand Suppl. 1990;358:58-62. doi: 10.1111/j.1600-0447.1990.tb05290.x.
The interaction potential of remoxipride was investigated with biperiden, warfarin, diazepam, and ethanol. The studies were conducted in 12 healthy volunteers each of whom received single doses of remoxipride, the interacting drug, and the combination in a randomized crossover design. Remoxipride and biperidene had no influence on each other's pharmacokinetics. The pharmacokinetics of warfarin enantiomers were uninfluenced by remoxipride. Ethanol and diazepam had no effect on the pharmacokinetics of remoxipride. The effect of remoxipride on the elevation of plasma prolactin levels was not modified by biperiden and the effect of warfarin on the prolongation of prothrombin time was uninfluened by remoxipride. Remoxipride showed no pharmacokinetic interaction with any of the drugs studied, nor was any pharmacodynamic interaction observed in the remoxipride versus biperiden and remoxipride versus warfarin studies.
研究了瑞莫必利与比哌立登、华法林、地西泮和乙醇的相互作用潜力。研究在12名健康志愿者中进行,每位志愿者均接受单剂量的瑞莫必利、相互作用药物以及二者组合,采用随机交叉设计。瑞莫必利和比哌立登对彼此的药代动力学没有影响。华法林对映体的药代动力学不受瑞莫必利影响。乙醇和地西泮对瑞莫必利的药代动力学没有影响。比哌立登未改变瑞莫必利对血浆催乳素水平升高的作用,瑞莫必利也未影响华法林对凝血酶原时间延长的作用。瑞莫必利与所研究的任何药物均未显示药代动力学相互作用,在瑞莫必利对比哌立登和瑞莫必利对华法林的研究中也未观察到任何药效学相互作用。